[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
An adenocarcinoma of the parotid gland is a rare tumor and little is known about the efficacy of chemotherapy as a method of treatment. Four patients with a metastatic, or recurrent adenocarcinoma of the parotid gland were treated with a combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin C (FAM): 5-fluorouracil 330-500 mg/m2, d1-3, q3w or tegafur 400-600 mg/m2 p.o. adriamycin 30-40 mg/m2 q3w, and mitomycin C 3-10 mg/m2, q1-2w. One patient with a lung metastasis showed a good partial response lasting for 19 months and another patient who was resistant to CDDP plus the adriamycin combination, having a lymph node, bone, and bone marrow metastases, had a partial response lasting for 31 months. Results have indicated that adriamycin is one of the effective therapeutic drugs and that FAM combination chemotherapy can provide some efficacy against a parotid cancer.
Inoue
K
K
Dept. of Clinical Oncology, Cancer Institute Hospital.
Horikoshi
N
N
Mukaiyama
T
T
Ogawa
M
M
Kuraishi
Y
Y
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010307:Parotid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil